natgillin/translations-raw huggingface dataset:
Because for technological reasons, in conventional veneer processing, it is not possible to assemble such narrow strips of veneer, said aesthetics in veneer are only realizable by the process according to the invention. Modification 
Budući da iz tehnoloških razloga, u običnom postupku obrade furnira, nije moguće spajati takve neravne trake od furnira, takav estetski izgled kod furnira je moguće ostvariti samo kod postupka koji je u skladu s ovim izumom.
The use according to claim 5, where dose a is within the range of from 10 to 55 wt.-% of dose d, where dose b is within the range of from 35 to 75 wt.-% of dose d, and where dose c is within the range of from 60 to 95 wt.-% of dose d. 
Lijek prema patentnom zahtjevu 10, naznačen time da je doza a unutar raspona od 10 do 65 % po težini doze c i da je doza b unutar raspona od 35 do 90 % po težini doze c.
Use of microparticles according to any one of claims 1 to 8 or of a pharmaceutical composition according to any one of claims 7 to 10 for the preparation of a medicament for the treatment of a disease or disorder with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion. 
Uporaba mikročestica u skladu s bilo kojim zahtjevom 1 do 6 ili farmaceutskog pripravka u skladu s bilo kojim zahtjevom 7 do 10, naznačena time, da se koristi za pripravu lijeka za liječenje bolesti ili poremećaja s etiologijom koja obuhvaća ili je povezana s viškom sekrecije GH- i/ili IGF-1. t>&
A method according to numbered embodiment 1 or numbered embodiment 2, wherein the fiberising apparatus comprises four rotors. 
Postupak sukladno patentnom zahtjevu 1 ili 2, pri čemu uređaj za izradu vlakana sadrži četiri rotora.
The article of Figure 3 has the advantage that the air introduced into the void space 97 contains less carbon oxidation products because it is not drawn through the burning fuel. 
Proizvod sa SI. 3 ima prednost da zrak koji se uvodi u prostor 97 sadrži manje oksidacijskih proizvoda ugljika zato što se ne uvlači kroz upaljeno gorivo.
determining whether less of said complex is formed in the presence of the test compound than in the absence of the test compound; 
(c) određivanje da li se manje navedenog kompleksa formira u prisutnosti test spoja nego li u odsutnosti test spoja; pri čemu je navedeno određivanje indikativno da je test spoj GLP-1 sekretogog;
5, in the first part 111 of the handle 11 the triangular arrangement of the spines 16, 17, 18 is oriented with an apex pointing in a direction opposite to the bristle direction shown by the arrow. 
Četkica za zube (10), u skladu s patentnim zahtjevom 2, naznačena time što se sve prečke (16, 17, 18) sreću uz prvi i drugi kraj (12, 13) drške (11).
The compound of claim 1 having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, and wherein 
Rui N h ili njegova farmaceutski prihvatljiva sol ili solvat, ili njegov njegov enantiomer ili dijastereomer, te gdje
The dryer of claim 4 in which the apertured plates (70, 80) are constructed with baffles which incline downwardly over the apertures in the plates (70, 80) and into the vertical path when the plates (70, 80) are moving downwardly along the vertical path. 
Sušilica prema patentnom zahtjevu 4 kod koje su ploče (70, 80) sa otvorima konstruirane sa odbojnim pločama koje su nagnute prema dole preko otvora u pločama (70, 80) 1 u vertikalnoj putanji kada se ploče (70, 80) pomiču prema dole duž vertikalne putanje.
The aqueous pharmaceutical formulation of claim 27, wherein the analogue of exendin-4 is selected from the group consisting of lixisenatide, exenatide, and liraglutide. 
Vodena formulacija u skladu s patentnim zahtjevom 1, naznačena time što sadrži analog eksendina-4, kojeg se bira iz skupine koju čine liksisenatid, eksenatid i liraglutid.
Ra, Rb, Rc, and Rd are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocyclic, aryl, substituted aryl, acyl, substituted acyl, SO2-alkyl, amino, substituted amino, and NO; or Ra and Rb together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, or thiomorpholino ring; or Rb and Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, or thiomorpholino ring; and 
is H, NRaRb, Cl, F, ORa, SRa, NHCORa, NHSO2Ra, NHCONHRa, CN, alkil, aril, ONRaRb, ili NRaC(O)ORb; jest nukleozidna šećerna skupina; Ra, Rb, RC,i Rd biraju se neovisno odabirom iz skupine koja se sastoji od H, alkil, supstituiranog alkila, alkenila, supstituiranog alkenil, alkinila, supstituiranog alkinila, cikloalkila, heterocikla, arila, supstituiranog arila, acila, supstituiranog acila, SO2 alkila, amino, supstituiranog amino i NO;
The blood brain barrier shuttle of claims 1 to 4, wherein the monovalent binding entity which binds to the blood brain barrier receptor comprises one scFab directed to the transferrin receptor, preferably a scFab recognizing an epitope in the transferrin receptor comprised within the amino acid sequence of Seq. Id. No. 14, 15 or 16. 
Prijenosnik za krvno-moždanu barijeru, naznačen time, da obuhvaća moždani efektor, povezivač i monovalentni vezivni entitet koji se veže na receptor transferina, pri čemu povezivač spaja entitet efektora s monovalentnim vezivnim entitetom koji se veže na receptor transferina, gdje monovalentni vezivni entitet koji se veže na receptor transferina obuhvaća jedan scFab usmjeren na receptor transferina koji prepoznaje epitop na receptoru transferina koji je obuhvaćen unutar aminokiselinskog slijeda Seq. Id.
the ampule member is separate from the fluid chamber when in the first position; and 
pomicanje filterskog sklopa iz prve pozicije u drugu poziciju; i
These features, together with a breaking strain > 20%, make this type of hot rolled strip particularly suitable for fine shearing and hole formation by punching, as well as cold stamping of complex shapes. 
Ove karakteristike, zajedno sa plastičnom deformacijom > 20%, čine ovaj tip toplo valjane trake posebno pogodnim za fino rezanje 1 pravljenje rupa bušenjem, kao i hladno utiskivanje složenih oblika.
A mixing member as claimed in any one of the foregoing Claims, characterized in that said scraper (8) is made of plastic or metal. 
Članak za miješanje prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je navedeni strugač (8) izrađen iz plastike ili metala.
administering a composition comprising an effective amount of an antibody comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50; 
(i) (a) najmanje jednu varijabilnu regiju lakog lanca, spomenuta varijabilna regija lakog lanca obuhvaća: regija koja utvrđuje komplementarnost lakog lanca 1 (CDRL1) sekvence amino kiseline SEK ID BR: 46;
In a particularly preferred embodiment, the present light stabilising composition is used as an additive, particularly a light stabilising additive, in beverages bottled in green, clear (e.g. 
U naročito poželjnom ostvarenju, sadašnji pripravak za stabiliziranje na svjetlo se upotrebljava kao aditiv, naročito aditiv za stabiliziranje na svjetlo, u pićima flaširanim u zelenom, prozirnom (npr.
R2b represents a hydrogen atom, a fluorine atom, a chlorine atom, methyl, ethyl, methoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy; and R2c represents a hydrogen atom, a fluorine atom, a chlorine atom, methyl, monofluoromethyl, difluoromethyl or trifluoromethyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
b predstavlja atom vodika, atom fluora, atom klora, metil, etil, metoksi, monofluorometil, difluorometil, trifluorometil, difluorometoksi ili trifluorometoksi; po izboru gdje R2b predstavlja atom vodika, metil, etil, metoksi, monofluorometil, difluorometil, trifluorometil, difluorometoksi ili trifluorometoksi; i
The gene construction according to claim 4, wherein the serotype of the adeno-associated vector is 1, 2, 5, 7, 8 or 9. 
Genski konstrukt u skladu s patentnim zahtjevom 4, naznačen time što je serotip adenoasociranog vektora 1, 2, 5, 7,81ili9.
An oligosaccharide comprising an aminooxy group prepared by a method comprising the steps of claim 12 wherein the aminooxy compound is chosen from compounds of Formula III: wherein n is chosen from integers ranging from 1 to 10. An oligosaccharide of Formula 1 a or Formula 1 b. 
osiguravanje aminooksi spoja koji sadrži aminooksi skupinu i drugu reaktivnu skupinu, pri čemu je aminooksi spoj odabran od spojeva s Formulom III: pri čemu n je odabran od cijelih brojeva u rasponu od 1 do 10, P je odabran od amino zaštitnih skupina, i Y je druga reaktivna skupina; i
a plurality of active agent particles comprising crystalline glycopyrrolate, including any pharmaceutically acceptable salts, esters, or solvates thereof, wherein at least 90% of the active agent particle material by volume exhibits an optical diameter of 7 µm or less, said active agent particles are included in the suspension medium at a concentration sufficient to provide a delivered dose of glycopyrrolate of up 20 µg per actuation of the metered dose inhaler; and 
prva vrsta čestica aktivnog sredstva sadrži glikopirolat, uključujući bilo koje farmaceutski prihvatljive soli, estere, enantiomere, te smjese njihovih enantiomera ili solvata, gdje najmanje 90% prve vrste čestica aktivnog sredstva po volumenu pokazuje optički promjer od 7 µm ili manji, suspendirane u suspenzijskom mediju u koncentraciji dovoljnoj da osigura unesenu dozu glikopirolata od do 80 µg po aktuaciji inhalatora za odmjerene doze;
is selected from phenyl, substituted phenyl, benzyl, substituted benzyl, biphenyl, substituted biphenyl, biphenylmethylene, substituted biphenylmethylene, naphthyl, substituted naphthyl, naphthylmethylene, and substituted nahpthylmethylene, or a pharmaceutically compatible salt thereof. 
je odabran od fenila, supstituiranog fenila, benzila, supstituiranog benzila, bifenila, supstituiranog bifenila, bifenilmetilena, supstituiranog bifenilmetilena, naftila, supstituiranog naftila, naftilmetilena, i supstituiranog naftilmetilena, ili njihova farmaceutski kompatibilna sol.
A bed arrangement having adaptive properties, comprising: 
Krevet (1) koji ima prilagodljiva svojstva, koji obuhvaća:
A process for separation of a compound of Formula VIII, Formula XXI, Formula XXV or Formula XXX or as defined in any of the preceding claims into diastereomer pairs or single diastereomers by preparative thin layer chromatography or by HPLC using an achiral or chiral column. 
Postupak odvajanja spoja Formule VIII, Formule XXI, Formule XXV ili Formule XXX ili spoja sukladno definicijama u bilo kojem prethodnom patentnom zahtjevu u dijastereomerske parove ili pojedinačne dijastereomere, naznačen time, da se provodi preparativnom tankoslojnom kromatografijom ili HPLC-om na kiralnoj ili akiralnoj koloni.
With regard to the water contents, the aqueous ethanol preferably contains 20 to 99.9 vol % of ethanol, and the aqueous acetone preferably contains 20 to 99.9 vol % of acetone. 
Postupak proizvodnje sastava koji sadrži piceatanol, prema zahtjevu 11, naznačen time, da vodeni aceton sadrži od 20 do 99,9 volumenskih % acetona.
The method according to claim 1, wherein the step of evaluating the signal light comprises determination of a load on the rail, measurement of speed of passing trains, detection of direction of passing trains, wheel damages of trains on the rail and/or train classification of passing trains. 
Primjena prema jednom od zahtjeva 4 do 5, pri čemu evaluacija obuhvaća određivanje opterećenja na tračnici (320), mjerenje brzine, prepoznavanje smjera vlakova koji prolaze, kvarova na kotačima vlakova na tračnici (320) i/ili klasifikaciju vlakova koji prolaze.
The invention also provides a method for the preparation of a catalyst for the catalytic decomposition of N2O in an N2O- and NOx-containing gas, where the catalyst contains a zeolite and the preparation of the catalyst involves the simultaneous loading of the zeolite with a first metal chosen from a group of noble metals, comprising ruthenium, rhodium, palladium, silver, rhenium, osmium, iridium, platinum and gold, in particular from a group of noble metals comprising ruthenium and platinum, and with a second metal chosen from a group of transition metals, comprising chromium, manganese, iron, cobalt, nickel and copper, especially iron. 
HR P20120556 T1 PATENTNI ZAHTJEVI naa on Postupak katalitičke razgradnje N2O u plinu koji sadrži NO i NO, u prisutnosti katalizatora, naznačen time što se plin koji sadrži N2O 1 NO, dovodi u kontakt s katalizatorom, gdje katalizator sadrži zeolit napunjen prvim metalom, kojeg se bira iz skupine plemenitih metala koju čine rutenij i platina, i drugim metalom, kojeg se bira iz skupine prijelaznih metala koju čini željezo, gdje se zeolit bira iz skupine koju čine FER 1 BEA, gdje se punjenje zeolita metalima provodi istodobnim punjenjem zeolita plemenitim metalom i prijelaznim metalom.
The size of capsules should be chosen in accordance with the specified formulation of the agent according to the present invention. 
Sredstvo sukladno bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time da je netolerancija fruktoze petoterancija crijevne fruktoze.
Hardening said mortar setting free said opposite sides of said elements of transparent to light material, suitable to form the inlet and the outlet of said opening, and taking out the finished panel from the formwork. 
€) očvršćavanjem spomenutog morta, pri čemu su spomenute suprotne strane spomenutih elemenata od materijala prozirnog za svijetlost, koji su prilagođeni za formiranje ulaza i izlaza spomenutog otvora, ostale slobodne 1 vađenjem gotove ploče iz okvira.
The starting sample and the filtrate were tested for SDS and IL-2 levels. 
Početni uzorak i filtrat su testirani na razine SDS i IL-2.
Granulate the powder mixture of step (l)-c OR (I') with a binder solution prepared in step II in a high speed mixer and dry the granules in a fluid bed dryer. 
(III) Granulirajte mješavinu praha iz koraka (I)-c ili (I) s otopinom veziva pripremljenom u koraku II u mikseru s velikom brzinom i osušite granule u sušioniku s tekućom podlogom.
The conditioning and priming step in the process of the preparation of the drug delivery devices is done to obtain a determined rate of release of a specific drug. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 14, naznačen time što čvrsta formulacije lijeka sadrži farmaceutski prihvatljiv nosač.
R9A, R9B, R15A and R15B are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; 
A, R9B, R15A i R15B su neovisno vodik, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, nesupstituirani cikloalkil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani aril ili supstituirani ili nesupstituirani heteroaril;
An isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody for use in treating a tumor in a human patient, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, and is conjugated to a cytotoxic agent. 
Izolirano protutijelo receptora epidermalnog faktora rasta (anti-EGFR-protutijelo), naznačeno time, da navedeno protutijelo sadrži varijabilno područje jakog lanca, koje ima aminokiselinsku sekvencu sadržanu u SEQ ID NO:164 i varijabilno područje slabog lanca, koje ima aminokiselinsku sekvencu sadržanu u SEQ ID NO:166.
This invention is also directed to a composition comprising (a) at least one compound selected from compounds of Formula 1, N -oxides, and salts thereof, wherein 
PATENTNI ZAHTJEVI 1. Kompozicija koja sadrži (a) najmanje jedan spoj izabran od spojeva formule 1, njihovih N-oksida i soli, Q
The compound for use according to claim 6, wherein the diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel are selected from the group consisting of inflammatory diseases, autoimmune diseases, allergic disorders, organ transplant, cancer and cardiovascular disorders. 
Spoj za uporabu prema patentnom zahtjevu 6, pri čemu su bolesti, poremećaji, sindromi 1li stanja povezani sa modulacijom kalcijeva kanala aktiviranog oslobađanjem kalcija (CRAC) izabrani iz grupe koja se sastoji od inflamatornih bolesti, autoimunih bolesti, alergijskih poremećaja, transplantacije organa, kanrcinoma i kardiovaskularnih poremećaja,
Device according to claims 8 or 9, characterized in that the format or dimension of the cross section of the fluid injection (11) and/or of the fluid discharge (12) can correspond substantially to the format and dimension of the respective closing element (5e, 5s). 
10. Uređaj u skladu s patentnim zahtjevom 8 ili 9, naznačen time, da oblik 1 dimenzije poprečnog presjeka ubrizgavanja tekućine (11) 1 / ili pražnjenja tekućine (12) u biti mogu odgovarati po obliku i dimenzijama odgovarajućim elementima za zatvaranje (5e, 5s).
At room temperature and with moderate agitation, sodium acetate dissolved in methanol (11 % wt/vol) is added to the isopropyl acetate solution of compound (e) such that a molar ratio of sodium acetate to compound (e) of 1.3 is achieved. 
Na sobnoj temperaturi, te uz umjereno miješanje, natrijev acetat se otopi u metanolu (11 % tež./vol. ekv.), te doda u izopropil-acetatnu otopinu spoja (e), tako da se postigne molarni odnos natrijevog acetata prema spoju (e) od 1,3.
Another aspect of the invention is a compound of formula I where n is 1 and ring A is piperidinyl substituted with 0-2 halo substituents. 
O E Spoj iz patentnog zahtjeva I gdje n je 1 i prsten A je piperidinil supstituiran sa 0-2 halo supstituenata.
The method of claim 2, wherein the neuroleptic agent is selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant. The method of claim 1, wherein the compound is 
Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, nadalje obuhvaća tvar odabranu iz grupe koja sadrži sertindol, olanzapin, risperidon, kvetiapin, aripiprazol, haloperidol, klozapin, ziprasidon i osanetant.
oxidizing a compound represented by the formula (I-2): wherein R3, X and m are as defined above, 
[image] pri čemu su R3, X i m kao što je definirano gore, reakcija spoja prikazanog formulom (I-3):
According to an aspect of some embodiments of the present invention there is provided an article of manufacture comprising a packaging material which comprises a label for use in treating a medical condition requiring connective tissue regeneration and/or repair, the packaging material packaging a pharmaceutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue. 
Proizvodni artikl koji sadrži ambalažni materijal na kojem je uputa, naznačen time što je namijenjen upotrebi u liječenju stanja koje se bira iz skupine koju čine ishemija, stanje kod kojeg je potrebno regeneriranje vezivnog tkiva i stanje kod kojeg je potreban popravak vezivnog tkiva, gdje je navedeni ambalažni materijal pakiranje za farmaceutski djelotvornu količinu adherentnih stanica posteljice ili masnih stanica.
In vitro release of the active ingredient was determined as in Example 1 and was: Released 
Oslobađanje djelatne tvari in-vitro određeno je kao u Primjeru 1 i iznosilo je:
The pharmaceutical composition of claim 1, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, crosslinked carboxymethyl cellulose, and low-substituted hydroxylpropylcellulose. The pharmaceutical composition of claim 1, wherein the sugar alcohol or saccharide is selected from the group consisting of sucralose, lactose, sucrose, maltose, mannitol, sorbitol, xylitol, maltitol, and mixtures thereof. 
Farmaceutski pripravak prema patentnim zahtjevima 4, 5, 6, 7, 8, 9, ili 10, naznačen time što je dezintegrant odabran iz grupe koji se sastoji od krospovidona, natrij škrob glikolata, umrežene karboksimetil celuloze, i nisko-supstituisane hidroksipropil celuloze, i pri čemu je šećerni alkohol ili saharid odabran iz grupe koja se sastoji od sukraloze, laktoze, saharoze, maltoze, manitola, sorbitola, ksilitola, maltitola, i njihovih smjesa.
Use according to any of claims 17 or 18, characterised in that the ocular inflammation and/or pain are associated to: post-surgical states after eye surgery; or allergic conjunctivitis, viral conjunctivitis, bacterial conjunctivitis, blepharitis, uveitis, iridocyclitis, intermediate uveitis, chorioretinitis, scleritis, episcleritis, retinitis, or keratitis; or 
Vodeni očni farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što su upala i/ili bol u oku povezani s: – postoperativnim stanjima nakon kirurškog zahvata na oku; ili – alergijskim konjunktivitisom, virusnim konjunktivitisom, bakterijskim konjunktivitisom, blefaritisom, uveitisom, iridociklitisom, intermedijarnim uveitisom, korioretinitisom, skleritisom, episkleritisom, retinitisom ili keratitisom; ili – suhim keratokonjunktivitisom; ili – ozljedom oka uzrokovane traumom, opeklinom, zračenjem, unošenjem stranog tijela ili kontaktom s kemijskim sredstvima; ili – upotrebom kontaktnih leća.
Solution for wood preservation according to the present invention offers environmentally acceptable protection of wood against most important wood decay fungi, including white rot, brown rot species as well as copper tolerant isolates. 
Otopina za konzerviranje drva prema ovom izumu nudi zaštitu drva prihvatljivu za okoliš, protiv najvažnijeg gljivičnog propadanja drva, uključujući bijelu trulež, vrste smeđe truleži, kao i izolate otporne na bakar.
Use according to claim 11 or an antibody or fragment according to claim 12, wherein said arthritis is chronic rheumatoid arthritis or said inflammatory bowel disease is Crohn's disease or ulcerative colitis. 
Uporaba u skladu s patentnim zahtjevom 10 ili antitijelo ili fragment u skladu s patentnim zahtjevom 11, naznačena time, da je navedeni artritis kronični reumatoidni artritis, a navedena upalna bolest crijeva Chronova bolest ili ulcerozni colitis.
A dispenser according to any preceding claim, wherein the body comprises a guide for guiding the slideable motion of the cam follower base in the longitudinal axis, the guide being shaped to receive the base of the cam follower in a slideable engagement. 
Dispenzer u skladu sa patentnim zahtjevom 28, gdje tijelo (1) sadrži vođicu (230, 220) pokretača brojača koja je konfigurirana da navodi pokretača (206) brojača u tijelo tako da se spriječi rotacija pokretača brojača u longitudinalnoj osi.
Thionyl chloride (32 g) was added and the reaction mixture heated to 60-70° C. and maintained for 30 min. 
Dodan je tionil klorid (32 g) te je reakcijska smjesa zagrijana na 60-70 "C te održavana tijekom 30 minuta.
Both in the first and in the second case of the connection of the third cord 11 of the cable 9 to OWT 5 directly or via the common cord 8, its induction heating occurs by high-frequency currents. 
I u prvom i u drugom slučaju povezivanja treće žice 11 kabla 9 na CNI 5 izravno ili preko zajedničke žice 8, njegovo se indukcijsko zagrijavanje zbiva pomoću struja visoke frekvencije.